On September 25, 2023, Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a genome-wide methylome approach, announced the completion of a $48 million financing. The round includes existing investors F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, and RA Capital Management, as well as new investor Labcorp. Wilson Sonsini Goodrich & Rosati advised Adela on patent matters related to the transaction.

The proceeds from the financing will be used to advance Adela's technology platform and commercialize Adela's first product for MRD monitoring, while further developing a multi-cancer early detection (MCED) product. Adela has raised $108 million total to date.

The Wilson Sonsini team that advised Adela on patent matters related to the transaction included Ali Alemozafar, Vern Norviel, Rona Lamiquiz, Sarah Cohen, and Esther Cynn.

For more information, please see Adela's news release.